Trial Outcomes & Findings for Pharmacokinetic Study of IV Artesunate to Treat Children With Severe Malaria (NCT NCT05750459)

NCT ID: NCT05750459

Last Updated: 2026-06-18

Results Overview

Population Pharmacokinetic (PK) modeling was conducted to derive Cmax from the concentration of DHA. The final model fit was a 1-compartment disposition of DHA with covariates for age and baseline bilirubin.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

90 participants

Primary outcome timeframe

Day 1(Sampling windows were defined as 0 (pre-dose), 0-1 hour, 1 - 2.5, 2.5-4, 4-6 and 6-24 hours post first on-study dose of IV artesunate)

Results posted on

2026-06-18

Participant Flow

The study population included participants aged 6 months through 14 years old residing in Tororo District, Uganda, who met all eligibility criteria, including a diagnosis of severe malaria. Ninety participants were enrolled between 29 November 2023 and 13 October 2024.

Participant milestones

Participant milestones
Measure
Standard of Care IV Artesunate
Participants weighing \<20 kg received IV artesunate at a dose of 3.0 mg/kg/dose and participants weighing =20 kg received 2.4 mg/kg/dose at times 0, 12, and 24 hours relative to time of first dose and then once daily at 48 and 72 hours until oral treatment could be substituted. Each participant was scheduled to receive a minimum of three doses. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
Overall Study
STARTED
90
Overall Study
COMPLETED
83
Overall Study
NOT COMPLETED
7

Reasons for withdrawal

Reasons for withdrawal
Measure
Standard of Care IV Artesunate
Participants weighing \<20 kg received IV artesunate at a dose of 3.0 mg/kg/dose and participants weighing =20 kg received 2.4 mg/kg/dose at times 0, 12, and 24 hours relative to time of first dose and then once daily at 48 and 72 hours until oral treatment could be substituted. Each participant was scheduled to receive a minimum of three doses. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
Overall Study
Death
1
Overall Study
Withdrawal by Subject
4
Overall Study
Failure to meet enrollment criteria
2

Baseline Characteristics

Weight-for-age Z-score was calculated for participants younger than 60 months according to the WHO Child Growth Standards (2006).

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Standard of Care IV Artesunate
n=90 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
Age, Categorical
<=18 years
90 Participants
n=90 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
n=90 Participants
Age, Categorical
>=65 years
0 Participants
n=90 Participants
Age, Continuous
5.65 years
STANDARD_DEVIATION 3.42 • n=90 Participants
Age, Customized
6-11 months
5 Participants
n=90 Participants
Age, Customized
1-2 years
20 Participants
n=90 Participants
Age, Customized
3-5 years
23 Participants
n=90 Participants
Age, Customized
6-11 years
37 Participants
n=90 Participants
Age, Customized
12-14 years
5 Participants
n=90 Participants
Sex: Female, Male
Female
46 Participants
n=90 Participants
Sex: Female, Male
Male
44 Participants
n=90 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=90 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
90 Participants
n=90 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=90 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=90 Participants
Race (NIH/OMB)
Asian
0 Participants
n=90 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=90 Participants
Race (NIH/OMB)
Black or African American
90 Participants
n=90 Participants
Race (NIH/OMB)
White
0 Participants
n=90 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=90 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=90 Participants
Region of Enrollment
Uganda
90 Participants
n=90 Participants
Weight-for-Age Z-score
-0.711 z-score
STANDARD_DEVIATION 1.723 • n=39 Participants • Weight-for-age Z-score was calculated for participants younger than 60 months according to the WHO Child Growth Standards (2006).
Height-for-Age Z-score
-1.099 z-score
STANDARD_DEVIATION 2.037 • n=39 Participants • Height-for-age Z-score was calculated for participants younger than 60 months according to the WHO Child Growth Standards (2006).

PRIMARY outcome

Timeframe: Day 1(Sampling windows were defined as 0 (pre-dose), 0-1 hour, 1 - 2.5, 2.5-4, 4-6 and 6-24 hours post first on-study dose of IV artesunate)

Population: The analysis population for the population PK modeling included all participants who received at least one on-study dose of IV artesunate and at least one DHA concentration data were available.

Population Pharmacokinetic (PK) modeling was conducted to derive Cmax from the concentration of DHA. The final model fit was a 1-compartment disposition of DHA with covariates for age and baseline bilirubin.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=90 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
Maximum Concentration (Cmax) of Dihydroartemisinin (DHA)
4,361.09 ug/L

PRIMARY outcome

Timeframe: Day 1(Sampling windows were defined as 0 (pre-dose), 0-1 hour, 1 - 2.5, 2.5-4, 4-6 and 6-24 hours post first on-study dose of IV artesunate)

Population: The analysis population for the population PK modeling included all participants who received at least one on-study dose of IV artesunate and at least one DHA concentration data were available.

Population PK modeling was conducted to derive AUC0-12 from the concentration of DHA. The final model fit was a 1-compartment disposition of DHA with covariates for age and baseline bilirubin. Day 1 (Sampling windows were defined as 0 (pre-dose), 0-1 hour, 1 - 2.5, 2.5-4, 4-6 and 6-24 hours post first on-study dose of IV artesunate)

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=90 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
Area Under the Curve Over 0-12 Hours (AUC0-12) of DHA
4,417.88 ug*h/L

PRIMARY outcome

Timeframe: Day 1 (Sampling windows were defined as 0 (pre-dose), 0-1 hour, 1 - 2.5, 2.5-4, 4-6 and 6-24 hours post first on-study dose of IV artesunate)

Population: The analysis population for the population PK modeling included all participants who received at least one on-study dose of IV artesunate and at least one DHA concentration data were available.

Population PK modeling was conducted to derive t1/2 from the concentration of DHA. The final model fit was a 1-compartment disposition of DHA with covariates for age and baseline bilirubin.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=90 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
Half-life (t1/2) of DHA
0.74 h
Interval 0.39 to 1.5

PRIMARY outcome

Timeframe: Day 1(Sampling windows were defined as 0 (pre-dose), 0-1 hour, 1 - 2.5, 2.5-4, 4-6 and 6-24 hours post first on-study dose of IV artesunate)

Population: The analysis population for the population PK modeling included all participants who received at least one on-study dose of IV artesunate and at least one DHA concentration data were available.

Population Pharmacokinetic (PK) modeling was conducted to derive PK parameters from the concentration of DHA. The final model fit was a 1-compartment disposition of DHA with covariates for age and baseline bilirubin. From the simulation, the Tmax was assumed to be 0 as the simulation replicates artesunate administered as an IV bolus directly into the central compartment.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=90 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
Time to Cmax (Tmax) of DHA
0 h
Interval 0.0 to 0.0

PRIMARY outcome

Timeframe: Baseline, 24 hours post-first IV Artesunate dose, 48 hours post-first IV Artesunate dose, Time of completion of planned IV Artesunate dosing (72 hours post-first IV Artesunate dose), and Time of first hospital discharge (up to day 9)

Population: The primary PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available.

Temperature was recorded approximately every 6 hours until 6 hours post-parasite clearance and at least daily until discharge along with scheduled follow-up visits. Change from baseline in temperature was reported at pre-defined timepoints: 24 and 48 hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time of first hospital discharge. Primary exposure-response analyses were performed to assess the relationship between DHA PK Parameters (AUC0-12, Cmax, and t1/2) and temperature. Many participants did not have unique measurements collected for each of the four timepoints defined, therefore these participants were using the same values at multiple timepoints. To meet the independence assumption of the Benjamini-Hochberg procedure, only 24-hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time to first hospital discharge had models fit and were assessed for significance for temperature.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=87 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
Change From Baseline in Temperature in the Primary Analysis Population
24 hours post-first IV Artesunate dose
-1.30 degrees C
Interval -4.3 to 2.3
Change From Baseline in Temperature in the Primary Analysis Population
48 hours post-first IV Artesunate dose
-1.80 degrees C
Interval -4.6 to 0.5
Change From Baseline in Temperature in the Primary Analysis Population
Time of completion of planned IV Artesunate dosing
-1.30 degrees C
Interval -4.3 to 1.5
Change From Baseline in Temperature in the Primary Analysis Population
Time of first hospital discharge
-1.9 degrees C
Interval -4.3 to 0.4

PRIMARY outcome

Timeframe: Baseline, 24 hours post-first IV Artesunate dose, 48 hours post-first IV Artesunate dose, Time of completion of planned IV Artesunate dosing (72 hours post-first IV Artesunate dose), and Time of first hospital discharge (up to day 9)

Population: Sensitivity analyses were conducted on the subset of the PD analysis population who did not receive any IV artesunate or other artemisinin-based therapy before enrollment. The PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available.

Temperature was recorded approximately every 6 hours until 6 hours post-parasite clearance and at least daily until discharge along with scheduled follow-up visits. Change from baseline in temperature was reported at pre-defined timepoints: 24 and 48 hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time of first hospital discharge. Primary exposure-response analyses were performed to assess the relationship between DHA PK parameters (AUC0-12, Cmax, and t1/2) and temperature. Many participants did not have unique measurements collected for each of the four timepoints defined, therefore these participants were using the same values at multiple timepoints. To meet the independence assumption of the Benjamini-Hochberg procedure, only 24-hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time to first hospital discharge had models fit and were assessed for significance for temperature.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=63 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
Change From Baseline in Temperature in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
24 hours post-first IV Artesunate dose
-1.10 degrees C
Interval -4.3 to 2.3
Change From Baseline in Temperature in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
48 hours post-first IV Artesunate dose
-1.70 degrees C
Interval -4.3 to 0.4
Change From Baseline in Temperature in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Time of completion of planned IV Artesunate dosing
-1.05 degrees C
Interval -4.3 to 1.5
Change From Baseline in Temperature in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Time of first hospital discharge
-2.10 degrees C
Interval -4.3 to 0.4

PRIMARY outcome

Timeframe: Baseline, 24 hours post-first IV Artesunate dose, 48 hours post-first IV Artesunate dose, Time of completion of planned IV Artesunate dosing (72 hours post-first IV Artesunate dose), and Time of first hospital discharge (up to day 9)

Population: The primary PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available.

Systolic BP was recorded approximately every 6 hours until 6 hours post-parasite clearance and at least daily until discharge along with scheduled follow-up visits. Change from baseline in systolic BP was reported at pre-defined timepoints: 24 and 48 hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time of first hospital discharge. Primary exposure-response analyses were performed to assess the relationship between DHA PK parameters (AUC0-12, Cmax, and t1/2) and systolic BP. Many participants did not have unique measurements collected for each of the four timepoints defined, thus these participants were using the same values at multiple timepoints. To meet the independence assumption of the Benjamini-Hochberg procedure, only 24-hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time to first hospital discharge had models fit and were assessed for significance for systolic BP.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=87 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
Change From Baseline Systolic Blood Pressure (BP) in the Primary Analysis Population
Time of completion of planned IV Artesunate dosing
-1.0 mmHg
Interval -39.0 to 20.0
Change From Baseline Systolic Blood Pressure (BP) in the Primary Analysis Population
Time of first hospital discharge
-3.0 mmHg
Interval -41.0 to 27.0
Change From Baseline Systolic Blood Pressure (BP) in the Primary Analysis Population
24 hours post-first IV Artesunate dose
-1.0 mmHg
Interval -43.0 to 59.0
Change From Baseline Systolic Blood Pressure (BP) in the Primary Analysis Population
48 hours post-first IV Artesunate dose
0.0 mmHg
Interval -31.0 to 23.0

PRIMARY outcome

Timeframe: Baseline, 24 hours post-first IV Artesunate dose, 48 hours post-first IV Artesunate dose, Time of completion of planned IV Artesunate dosing (72 hours post-first IV Artesunate dose), and Time of first hospital discharge (up to day 9)

Population: Sensitivity analyses were conducted on the subset of the PD analysis population who did not receive any IV artesunate or other artemisinin-based therapy before enrollment. The PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available.

Systolic BP was recorded approximately every 6 hours until 6 hours post-parasite clearance and at least daily until discharge along with scheduled follow-up visits. Change from baseline in systolic BP was reported at pre-defined timepoints: 24 and 48 hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time of first hospital discharge. Primary exposure-response analyses were performed to assess the relationship between DHA PK parameters (AUC0-12, Cmax, and t1/2) and systolic BP. Many participants did not have unique measurements collected for each of the four timepoints defined, thus these participants were using the same values at multiple timepoints. To meet the independence assumption of the Benjamini-Hochberg procedure, only 24-hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time to first hospital discharge had models fit and were assessed for significance for systolic BP.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=63 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
Change From Baseline Systolic BP in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
48 hours post-first IV Artesunate dose
0.0 mmHg
Interval -31.0 to 23.0
Change From Baseline Systolic BP in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Time of completion of planned IV Artesunate dosing
-1.0 mmHg
Interval -19.0 to 20.0
Change From Baseline Systolic BP in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Time of first hospital discharge
0.0 mmHg
Interval -41.0 to 27.0
Change From Baseline Systolic BP in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
24 hours post-first IV Artesunate dose
-2.5 mmHg
Interval -33.0 to 59.0

PRIMARY outcome

Timeframe: Baseline, 24 hours post-first IV Artesunate dose, 48 hours post-first IV Artesunate dose, Time of completion of planned IV Artesunate dosing (72 hours post-first IV Artesunate dose), and Time of first hospital discharge (up to day 9)

Population: The primary PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available.

Diastolic BP was recorded approximately every 6 hours until 6 hours post-parasite clearance and at least daily until discharge along with scheduled follow-up visits. Change from baseline in diastolic BP was reported at pre-defined timepoints: 24 and 48 hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time of first hospital discharge. Primary exposure-response analyses were performed to assess the relationship between DHA PK parameters (AUC0-12, Cmax, t1/2) and diastolic BP. Many participants did not have unique measurements collected for each of the four timepoints defined, therefore these participants were using the same values at multiple timepoints. To meet the independence assumption of the Benjamini-Hochberg procedure, only 24-hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time to first hospital discharge had models fit and were assessed for significance for diastolic BP.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=87 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
Change From Baseline Diastolic BP in the Primary Analysis Population
24 hours post-first IV Artesunate dose
-0.5 mmHg
Interval -42.0 to 39.0
Change From Baseline Diastolic BP in the Primary Analysis Population
48 hours post-first IV Artesunate dose
-2.0 mmHg
Interval -35.0 to 26.0
Change From Baseline Diastolic BP in the Primary Analysis Population
Time of completion of planned IV Artesunate dosing
-1.5 mmHg
Interval -24.0 to 29.0
Change From Baseline Diastolic BP in the Primary Analysis Population
Time of first hospital discharge
-2.0 mmHg
Interval -38.0 to 31.0

PRIMARY outcome

Timeframe: Baseline, 24 hours post-first IV Artesunate dose, 48 hours post-first IV Artesunate dose, Time of completion of planned IV Artesunate dosing (72 hours post-first IV Artesunate dose), and Time of first hospital discharge (up to day 9)

Population: Sensitivity analyses were conducted on the subset of the PD analysis population who did not receive any IV artesunate or other artemisinin-based therapy before enrollment. The PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available.

Diastolic BP was recorded approximately every 6 hours until 6 hours post-parasite clearance and at least daily until discharge along with scheduled follow-up visits. Change from baseline in diastolic BP was reported at pre-defined timepoints: 24 and 48 hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time of first hospital discharge. Primary exposure-response analyses were performed to assess the relationship between DHA PK parameters (AUC0-12, Cmax, and t1/2) and diastolic BP. Many participants did not have unique measurements collected for each of the four timepoints defined, thus these participants were using the same values at multiple timepoints. To meet the independence assumption of the Benjamini-Hochberg procedure, only 24-hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time to first hospital discharge had models fit and were assessed for significance for diastolic BP.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=63 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
Change From Baseline Diastolic BP in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
24 hours post-first IV Artesunate dose
-1.5 mmHg
Interval -42.0 to 39.0
Change From Baseline Diastolic BP in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
48 hours post-first IV Artesunate dose
-1.0 mmHg
Interval -35.0 to 26.0
Change From Baseline Diastolic BP in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Time of first hospital discharge
-2.5 mmHg
Interval -38.0 to 27.0
Change From Baseline Diastolic BP in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Time of completion of planned IV Artesunate dosing
-1.5 mmHg
Interval -24.0 to 29.0

PRIMARY outcome

Timeframe: Baseline, 24 hours post-first IV Artesunate dose, 48 hours post-first IV Artesunate dose, Time of completion of planned IV Artesunate dosing (72 hours post-first IV Artesunate dose), and Time of first hospital discharge (up to day 9)

Population: The primary PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available.

Serum lactate was recorded daily until discharge along with scheduled follow-up visits. Change from baseline in serum lactate was reported at pre-defined timepoints: 24 and 48 hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time of first hospital discharge. Primary exposure-response analyses were performed to assess the relationship between DHA PK parameters (AUC0-12, Cmax, t1/2) and serum lactate. Many participants did not have unique measurements collected for each of the four timepoints defined, therefore these participants were using the same values at multiple timepoints. To meet the independence assumption of the Benjamini-Hochberg procedure, only 24-hours post-first IV artesunate and time of completion of planned IV artesunate dosing had models fit and were assessed for significance for serum lactate.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=87 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
Change From in Venous Serum Lactate in the Primary Analysis Population
24 hours post-first IV Artesunate dose
0.000 mmol/L
Interval -8.3 to 9.41
Change From in Venous Serum Lactate in the Primary Analysis Population
48 hours post-first IV Artesunate dose
-0.700 mmol/L
Interval -7.29 to 8.47
Change From in Venous Serum Lactate in the Primary Analysis Population
Time of completion of planned IV Artesunate dosing
-0.760 mmol/L
Interval -7.29 to 8.47
Change From in Venous Serum Lactate in the Primary Analysis Population
Time of first hospital discharge
-0.430 mmol/L
Interval -8.3 to 8.19

PRIMARY outcome

Timeframe: Baseline, 24 hours post-first IV Artesunate dose, 48 hours post-first IV Artesunate dose, Time of completion of planned IV Artesunate dosing (72 hours post-first IV Artesunate dose), and Time of first hospital discharge (up to day 9)

Population: Sensitivity analyses were conducted on the subset of the PD analysis population who did not receive any IV artesunate or other artemisinin-based therapy before enrollment. The PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available.

Serum lactate was recorded daily until discharge along with scheduled follow-up visits. Change from baseline in serum lactate was reported at pre-defined timepoints: 24 and 48 hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time of first hospital discharge. Primary exposure-response analyses were performed to assess the relationship between DHA PK parameters (AUC0-12, Cmax, t1/2) and serum lactate. Many participants did not have unique measurements collected for each of the four timepoints defined, therefore these participants were using the same values at multiple timepoints. To meet the independence assumption of the Benjamini-Hochberg procedure, only 24-hours post-first IV artesunate and time of completion of planned IV artesunate dosing had models fit and were assessed for significance for serum lactate.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=63 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
Change From in Venous Serum Lactate in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
24 hours post-first IV Artesunate dose
-0.090 mmol/L
Interval -8.3 to 9.41
Change From in Venous Serum Lactate in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Time of completion of planned IV Artesunate dosing
-0.865 mmol/L
Interval -7.29 to 8.47
Change From in Venous Serum Lactate in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Time of first hospital discharge
-0.445 mmol/L
Interval -8.3 to 8.19
Change From in Venous Serum Lactate in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
48 hours post-first IV Artesunate dose
-0.865 mmol/L
Interval -7.29 to 8.47

PRIMARY outcome

Timeframe: Baseline, 24 hours post-first IV Artesunate dose, 48 hours post-first IV Artesunate dose, Time of completion of planned IV Artesunate dosing (72 hours post-first IV Artesunate dose), and Time of first hospital discharge (up to day 9)

Population: The primary PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available.

Serum bicarbonate was recorded daily until discharge along with scheduled follow-up visits. Change from baseline in serum bicarbonate was reported at pre-defined timepoints: 24 and 48 hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time of first hospital discharge. Primary exposure-response analyses were performed to assess the relationship between DHA PK parameters (AUC0-12, Cmax, t1/2) and serum bicarbonate. Many participants did not have unique measurements collected for each of the four timepoints defined, therefore these participants were using the same values at multiple timepoints. To meet the independence assumption of the Benjamini-Hochberg procedure, only 24-hours post-first IV artesunate and time of completion of planned IV artesunate dosing had models fit and were assessed for significance for serum bicarbonate.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=87 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
Change From Baseline in Serum Bicarbonate in the Primary Analysis Population
24 hours post-first IV Artesunate dose
1.0 mmol/L
Interval -6.0 to 24.0
Change From Baseline in Serum Bicarbonate in the Primary Analysis Population
48 hours post-first IV Artesunate dose
2.0 mmol/L
Interval -10.0 to 13.0
Change From Baseline in Serum Bicarbonate in the Primary Analysis Population
Time of completion of planned IV Artesunate dosing
2.0 mmol/L
Interval -8.0 to 13.0
Change From Baseline in Serum Bicarbonate in the Primary Analysis Population
Time of first hospital discharge
1.0 mmol/L
Interval -10.0 to 13.0

PRIMARY outcome

Timeframe: Baseline, 24 hours post-first IV Artesunate dose, 48 hours post-first IV Artesunate dose, Time of completion of planned IV Artesunate dosing (72 hours post-first IV Artesunate dose), and Time of first hospital discharge (up to day 9)

Population: Sensitivity analyses were conducted on the subset of the PD analysis population who did not receive any IV artesunate or other artemisinin-based therapy before enrollment. The PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available.

Serum bicarbonate was recorded daily until discharge along with scheduled follow-up visits. Change from baseline in serum bicarbonate was reported at pre-defined timepoints: 24 and 48 hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time of first hospital discharge. Primary exposure-response analyses were performed to assess the relationship between DHA PK parameters (AUC0-12, Cmax, t1/2) and serum bicarbonate. Many participants did not have unique measurements collected for each of the four timepoints defined, therefore these participants were using the same values at multiple timepoints. To meet the independence assumption of the Benjamini-Hochberg procedure, only 24-hours post-first IV artesunate and time of completion of planned IV artesunate dosing had models fit and were assessed for significance for serum bicarbonate.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=63 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
Change From Baseline in Serum Bicarbonate in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
24 hours post-first IV Artesunate dose
1.0 mmol/L
Interval -6.0 to 24.0
Change From Baseline in Serum Bicarbonate in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
48 hours post-first IV Artesunate dose
2.0 mmol/L
Interval -8.0 to 13.0
Change From Baseline in Serum Bicarbonate in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Time of completion of planned IV Artesunate dosing
2.0 mmol/L
Interval -8.0 to 13.0
Change From Baseline in Serum Bicarbonate in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Time of first hospital discharge
1.0 mmol/L
Interval -6.0 to 13.0

PRIMARY outcome

Timeframe: 24 hours post-first IV Artesunate dose, 48 hours post-first IV Artesunate dose, Time of completion of planned IV Artesunate dosing (72 hours post-first IV Artesunate dose), and Time of first hospital discharge (up to day 9)

Population: The primary PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available.

Serum glucose was recorded daily until discharge along with scheduled follow-up visits. Change from baseline in serum glucose was reported at pre-defined timepoints: 24 and 48 hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time of first hospital discharge. Primary exposure-response analyses were performed to assess the relationship between DHA PK parameters (AUC0-12, Cmax, t1/2) and serum glucose. Many participants did not have unique measurements collected for each of the four timepoints defined, therefore these participants were using the same values at multiple timepoints. To meet the independence assumption of the Benjamini-Hochberg procedure, only 24-hours post-first IV artesunate and time of completion of planned IV artesunate dosing had models fit and were assessed for significance for serum glucose.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=87 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
Change From Baseline in Serum Glucose in the Primary Analysis Population
24 hours post-first IV Artesunate dose
0.15 mmol/L
Interval -4.7 to 7.6
Change From Baseline in Serum Glucose in the Primary Analysis Population
Time of completion of planned IV Artesunate dosing
-0.50 mmol/L
Interval -5.7 to 1.8
Change From Baseline in Serum Glucose in the Primary Analysis Population
Time of first hospital discharge
-0.10 mmol/L
Interval -4.4 to 7.6
Change From Baseline in Serum Glucose in the Primary Analysis Population
48 hours post-first IV Artesunate dose
-0.50 mmol/L
Interval -5.7 to 1.8

PRIMARY outcome

Timeframe: Baseline, 24 hours post-first IV Artesunate dose, 48 hours post-first IV Artesunate dose, Time of completion of planned IV Artesunate dosing (72 hours post-first IV Artesunate dose), and Time of first hospital discharge (up to day 9)

Population: Sensitivity analyses were conducted on the subset of the PD analysis population who did not receive any IV artesunate or other artemisinin-based therapy before enrollment. The PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available.

Serum glucose was recorded daily until discharge along with scheduled follow-up visits. Change from baseline in serum glucose was reported at pre-defined timepoints: 24 and 48 hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time of first hospital discharge. Primary exposure-response analyses were performed to assess the relationship between DHA PK parameters (AUC0-12, Cmax, t1/2) and serum glucose. Many participants did not have unique measurements collected for each of the four timepoints defined, therefore these participants were using the same values at multiple timepoints. To meet the independence assumption of the Benjamini-Hochberg procedure, only 24-hours post-first IV artesunate and time of completion of planned IV artesunate dosing had models fit and were assessed for significance for serum glucose.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=63 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
Change From Baseline in Serum Glucose in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
24 hours post-first IV Artesunate dose
0.10 mmol/L
Interval -4.7 to 7.6
Change From Baseline in Serum Glucose in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Time of completion of planned IV Artesunate dosing
-0.55 mmol/L
Interval -5.7 to 1.8
Change From Baseline in Serum Glucose in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Time of first hospital discharge
-0.10 mmol/L
Interval -4.4 to 7.6
Change From Baseline in Serum Glucose in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
48 hours post-first IV Artesunate dose
-0.55 mmol/L
Interval -5.7 to 1.8

PRIMARY outcome

Timeframe: Baseline, 24 hours post-first IV Artesunate dose, 48 hours post-first IV Artesunate dose, Time of completion of planned IV Artesunate dosing (72 hours post-first IV Artesunate dose), and Time of first hospital discharge (up to day 9)

Population: The primary PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available.

Total bilirubin was recorded daily until discharge along with scheduled follow-up visits. Change from baseline in total bilirubin was reported at pre-defined timepoints: 24 and 48 hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time of first hospital discharge. Primary exposure-response analyses were performed to assess the relationship between DHA PK parameters (AUC0-12, Cmax, t1/2) and total bilirubin. Many participants did not have unique measurements collected for each of the four timepoints defined, therefore these participants were using the same values at multiple timepoints. To meet the independence assumption of the Benjamini-Hochberg procedure, only 24-hours post-first IV artesunate and time of completion of planned IV artesunate dosing had models fit and were assessed for significance for total bilirubin.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=87 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
Change From Baseline in Total Bilirubin in the Primary Analysis Population
24 hours post-first IV Artesunate dose
-4.0 umol/L
Interval -35.0 to 20.0
Change From Baseline in Total Bilirubin in the Primary Analysis Population
48 hours post-first IV Artesunate dose
-11.0 umol/L
Interval -95.0 to 45.0
Change From Baseline in Total Bilirubin in the Primary Analysis Population
Time of completion of planned IV Artesunate dosing
-11.0 umol/L
Interval -95.0 to 5.0
Change From Baseline in Total Bilirubin in the Primary Analysis Population
Time of first hospital discharge
-6.0 umol/L
Interval -95.0 to 20.0

PRIMARY outcome

Timeframe: Baseline, 24 hours post-first IV Artesunate dose, 48 hours post-first IV Artesunate dose, Time of completion of planned IV Artesunate dosing (72 hours post-first IV Artesunate dose), and Time of first hospital discharge (up to day 9)

Population: Sensitivity analyses were conducted on the subset of the PD analysis population who did not receive any IV artesunate or other artemisinin-based therapy before enrollment. The PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available.

Total bilirubin was recorded daily until discharge along with scheduled follow-up visits. Change from baseline in total bilirubin was reported at pre-defined timepoints: 24 and 48 hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time of first hospital discharge. Primary exposure-response analyses were performed to assess the relationship between DHA PK parameters (AUC0-12, Cmax, t1/2) and total bilirubin. Many participants did not have unique measurements collected for each of the four timepoints defined, therefore these participants were using the same values at multiple timepoints. To meet the independence assumption of the Benjamini-Hochberg procedure, only 24-hours post-first IV artesunate and time of completion of planned IV artesunate dosing had models fit and were assessed for significance for total bilirubin.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=63 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
Change From Baseline in Total Bilirubin in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Time of completion of planned IV Artesunate dosing
-11.0 umol/L
Interval -65.0 to 5.0
Change From Baseline in Total Bilirubin in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Time of first hospital discharge
-5.0 umol/L
Interval -39.0 to 20.0
Change From Baseline in Total Bilirubin in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
24 hours post-first IV Artesunate dose
-3.5 umol/L
Interval -35.0 to 20.0
Change From Baseline in Total Bilirubin in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
48 hours post-first IV Artesunate dose
-11.0 umol/L
Interval -65.0 to 5.0

PRIMARY outcome

Timeframe: Baseline, 24 hours post-first IV Artesunate dose, 48 hours post-first IV Artesunate dose, Time of completion of planned IV Artesunate dosing (72 hours post-first IV Artesunate dose), and Time of first hospital discharge (up to day 9)

Population: The primary PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available.

Direct bilirubin was recorded daily until discharge along with scheduled follow-up visits. Change from baseline in direct bilirubin was reported at pre-defined timepoints: 24 and 48 hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time of first hospital discharge. Primary exposure-response analyses were performed to assess the relationship between DHA PK parameters (AUC0-12, Cmax, t1/2) and direct bilirubin. Many participants did not have unique measurements collected for each of the four timepoints defined, therefore these participants were using the same values at multiple timepoints. To meet the independence assumption of the Benjamini-Hochberg procedure, only 24-hours post-first IV artesunate and time of completion of planned IV artesunate dosing had models fit and were assessed for significance for direct bilirubin.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=87 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
Change From Baseline in Direct Bilirubin in the Primary Analysis Population
24 hours post-first IV Artesunate dose
-1.0 umol/L
Interval -26.0 to 7.0
Change From Baseline in Direct Bilirubin in the Primary Analysis Population
48 hours post-first IV Artesunate dose
-3.0 umol/L
Interval -69.0 to 40.0
Change From Baseline in Direct Bilirubin in the Primary Analysis Population
Time of completion of planned IV Artesunate dosing
-3.0 umol/L
Interval -69.0 to 3.0
Change From Baseline in Direct Bilirubin in the Primary Analysis Population
Time of first hospital discharge
-2.0 umol/L
Interval -26.0 to 7.0

PRIMARY outcome

Timeframe: Baseline, 24 hours post-first IV Artesunate dose, 48 hours post-first IV Artesunate dose, Time of completion of planned IV Artesunate dosing (72 hours post-first IV Artesunate dose), and Time of first hospital discharge (up to day 9)

Population: Sensitivity analyses were conducted on the subset of the PD analysis population who did not receive any IV artesunate or other artemisinin-based therapy before enrollment. The PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available.

Direct bilirubin was recorded daily until discharge along with scheduled follow-up visits. Change from baseline in direct bilirubin was reported at pre-defined timepoints: 24 and 48 hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time of first hospital discharge. Primary exposure-response analyses were performed to assess the relationship between DHA PK parameters (AUC0-12, Cmax, t1/2) and direct bilirubin. Many participants did not have unique measurements collected for each of the four timepoints defined, therefore these participants were using the same values at multiple timepoints. To meet the independence assumption of the Benjamini-Hochberg procedure, only 24-hours post-first IV artesunate and time of completion of planned IV artesunate dosing had models fit and were assessed for significance for direct bilirubin.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=63 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
Change From Baseline in Direct Bilirubin in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
24 hours post-first IV Artesunate dose
-1.0 umol/L
Interval -26.0 to 7.0
Change From Baseline in Direct Bilirubin in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
48 hours post-first IV Artesunate dose
-4.0 umol/L
Interval -69.0 to 3.0
Change From Baseline in Direct Bilirubin in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Time of completion of planned IV Artesunate dosing
-4.0 umol/L
Interval -69.0 to 3.0
Change From Baseline in Direct Bilirubin in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Time of first hospital discharge
-2.0 umol/L
Interval -26.0 to 7.0

PRIMARY outcome

Timeframe: Baseline, 24 hours post-first IV Artesunate dose, 48 hours post-first IV Artesunate dose, Time of completion of planned IV Artesunate dosing (72 hours post-first IV Artesunate dose), and Time of first hospital discharge (up to day 9)

Population: The primary PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available.

Hemoglobin was recorded daily until discharge along with scheduled follow-up visits. Change from baseline in hemoglobin was reported at pre-defined timepoints: 24 and 48 hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time of first hospital discharge. Primary exposure-response analyses were performed to assess the relationship between DHA PK parameters (AUC0-12, Cmax, t1/2) and hemoglobin. Many participants did not have unique measurements collected for each of the four timepoints defined, therefore these participants were using the same values at multiple timepoints. To meet the independence assumption of the Benjamini-Hochberg procedure, only 24-hours post-first IV artesunate and time of completion of planned IV artesunate dosing had models fit and were assessed for significance for hemoglobin.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=87 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
Change From Baseline in Hemoglobin in the Primary Analysis Population
24 hours post-first IV Artesunate dose
-0.70 g/dL
Interval -15.1 to 9.7
Change From Baseline in Hemoglobin in the Primary Analysis Population
48 hours post-first IV Artesunate dose
-0.80 g/dL
Interval -15.2 to 8.7
Change From Baseline in Hemoglobin in the Primary Analysis Population
Time of completion of planned IV Artesunate dosing
-0.80 g/dL
Interval -15.2 to 8.7
Change From Baseline in Hemoglobin in the Primary Analysis Population
Time of first hospital discharge
-0.70 g/dL
Interval -15.1 to 8.7

PRIMARY outcome

Timeframe: Baseline, 24 hours post-first IV Artesunate dose, 48 hours post-first IV Artesunate dose, Time of completion of planned IV Artesunate dosing (72 hours post-first IV Artesunate dose), and Time of first hospital discharge (up to day 9)

Population: Sensitivity analyses were conducted on the subset of the PD analysis population who did not receive any IV artesunate or other artemisinin-based therapy before enrollment. The PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available.

Hemoglobin was recorded daily until discharge along with scheduled follow-up visits. Change from baseline in hemoglobin was reported at pre-defined timepoints: 24 and 48 hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time of first hospital discharge. Primary exposure-response analyses were performed to assess the relationship between DHA PK parameters (AUC0-12, Cmax, t1/2) and hemoglobin. Many participants did not have unique measurements collected for each of the four timepoints defined, therefore these participants were using the same values at multiple timepoints. To meet the independence assumption of the Benjamini-Hochberg procedure, only 24-hours post-first IV artesunate and time of completion of planned IV artesunate dosing had models fit and were assessed for significance for hemoglobin.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=63 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
Change From Baseline in Hemoglobin in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
24 hours post-first IV Artesunate dose
-0.70 g/dL
Interval -15.1 to 9.7
Change From Baseline in Hemoglobin in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
48 hours post-first IV Artesunate dose
-0.80 g/dL
Interval -15.2 to 8.7
Change From Baseline in Hemoglobin in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Time of completion of planned IV Artesunate dosing
-0.80 g/dL
Interval -15.2 to 8.7
Change From Baseline in Hemoglobin in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Time of first hospital discharge
-0.70 g/dL
Interval -15.1 to 8.7

PRIMARY outcome

Timeframe: Baseline, 24 hours post-first IV Artesunate dose, 48 hours post-first IV Artesunate dose, Time of completion of planned IV Artesunate dosing (72 hours post-first IV Artesunate dose), and Time of first hospital discharge (up to day 9)

Population: The primary PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available.

Creatinine was recorded daily until discharge along with scheduled follow-up visits. Change from baseline in creatinine was reported at pre-defined timepoints: 24 and 48 hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time of first hospital discharge. Primary exposure-response analyses were performed to assess the relationship between DHA PK parameters (AUC0-12, Cmax, t1/2) and creatinine. Many participants did not have unique measurements collected for each of the four timepoints defined, therefore these participants were using the same values at multiple timepoints. To meet the independence assumption of the Benjamini-Hochberg procedure, only 24-hours post-first IV artesunate and time of completion of planned IV artesunate dosing had models fit and were assessed for significance for creatinine.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=87 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
Change From Baseline in Creatinine in the Primary Analysis Population
24 hours post-first IV Artesunate dose
-4.0 umol/L
Interval -22.0 to 21.0
Change From Baseline in Creatinine in the Primary Analysis Population
48 hours post-first IV Artesunate dose
-5.0 umol/L
Interval -41.0 to 15.0
Change From Baseline in Creatinine in the Primary Analysis Population
Time of completion of planned IV Artesunate dosing
-5.0 umol/L
Interval -41.0 to 15.0
Change From Baseline in Creatinine in the Primary Analysis Population
Time of first hospital discharge
-3.0 umol/L
Interval -39.0 to 21.0

PRIMARY outcome

Timeframe: Baseline, 24 hours post-first IV Artesunate dose, 48 hours post-first IV Artesunate dose, Time of completion of planned IV Artesunate dosing (72 hours post-first IV Artesunate dose), and Time of first hospital discharge (up to day 9)

Population: Sensitivity analyses were conducted on the subset of the PD analysis population who did not receive any IV artesunate or other artemisinin-based therapy before enrollment. The PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available.

Creatinine was recorded daily until discharge along with scheduled follow-up visits. Change from baseline in creatinine was reported at pre-defined timepoints: 24 and 48 hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time of first hospital discharge. Primary exposure-response analyses were performed to assess the relationship between DHA PK parameters (AUC0-12, Cmax, t1/2) and creatinine. Many participants did not have unique measurements collected for each of the four timepoints defined, therefore these participants were using the same values at multiple timepoints. To meet the independence assumption of the Benjamini-Hochberg procedure, only 24-hours post-first IV artesunate and time of completion of planned IV artesunate dosing had models fit and were assessed for significance for creatinine.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=63 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
Change From Baseline in Creatinine in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
24 hours post-first IV Artesunate dose
-4.0 g/dL
Interval -22.0 to 21.0
Change From Baseline in Creatinine in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
48 hours post-first IV Artesunate dose
-5.0 g/dL
Interval -24.0 to 11.0
Change From Baseline in Creatinine in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Time of completion of planned IV Artesunate dosing
-5.0 g/dL
Interval -24.0 to 11.0
Change From Baseline in Creatinine in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Time of first hospital discharge
-3.0 g/dL
Interval -24.0 to 21.0

PRIMARY outcome

Timeframe: Baseline, 24 hours post-first IV Artesunate dose, 48 hours post-first IV Artesunate dose, Time of completion of planned IV Artesunate dosing (72 hours post-first IV Artesunate dose), and Time of first hospital discharge (up to day 9)

Population: The PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available. Only participants who were assessed a BCS of 1 are shown.

Blantyre coma scale is an ordinal scale designed to assess malarial coma in children. Eye movement, best motor response, and best verbal response were assessed and scored. The total BCS score was then calculated as the sum of the scores for these three assessments with possible values of 0, 1, 2, 3, 4, or 5. Lower BCS values were indicative of impaired consciousness. BCS was recorded daily until discharge along with scheduled follow-up visits. The number of participants in each BCS were reported at pre-defined timepoints: baseline, 24 and 48 hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time of first hospital discharge. Due to the lack of variability in BCS scores, proportional odds mixed effects models to assess the relationship between BCS scores and each PK exposure parameter were not conducted. Instead, summary statistics of DHA AUC0-12 for BCS score of 1 by timepoint are presented.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=87 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
DHA AUC0-12 Summary Statistics for Participants With Blantyre Coma Score (BCS) of 1 in the Primary Analysis Population
Baseline
5357.830 ng*h/mL
Interval 5357.83 to 5357.83
DHA AUC0-12 Summary Statistics for Participants With Blantyre Coma Score (BCS) of 1 in the Primary Analysis Population
24 hours post-first IV Artesunate dose
5357.830 ng*h/mL
Interval 5357.83 to 5357.83
DHA AUC0-12 Summary Statistics for Participants With Blantyre Coma Score (BCS) of 1 in the Primary Analysis Population
48 hours post-first IV Artesunate dose
5357.830 ng*h/mL
Interval 5357.83 to 5357.83

PRIMARY outcome

Timeframe: Baseline, 24 hours post-first IV Artesunate dose, 48 hours post-first IV Artesunate dose, Time of completion of planned IV Artesunate dosing (72 hours post-first IV Artesunate dose), and Time of first hospital discharge (up to day 9)

Population: The PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available. Only participants who were assessed a BCS of 4 are shown.

Blantyre coma scale is an ordinal scale designed to assess malarial coma in children. Eye movement, best motor response, and best verbal response were assessed and scored. The total BCS score was then calculated as the sum of the scores for these three assessments with possible values of 0, 1, 2, 3, 4, or 5. Lower BCS values were indicative of impaired consciousness. BCS was recorded daily until discharge along with scheduled follow-up visits. The number of participants in each BCS were reported at pre-defined timepoints: baseline, 24 and 48 hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time of first hospital discharge. Due to the lack of variability in BCS scores, proportional odds mixed effects models to assess the relationship between BCS scores and each PK exposure parameter were not conducted. Instead, summary statistics of DHA AUC0-12 for BCS score of 4 by timepoint are presented.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=87 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
DHA AUC0-12 Summary Statistics for Participants With BCS of 4 in the Primary Analysis Population
Baseline
5271.585 ng*h/mL
Interval 4054.71 to 6488.46
DHA AUC0-12 Summary Statistics for Participants With BCS of 4 in the Primary Analysis Population
24 hours post-first IV Artesunate dose
6488.460 ng*h/mL
Interval 6488.46 to 6488.46
DHA AUC0-12 Summary Statistics for Participants With BCS of 4 in the Primary Analysis Population
48 hours post-first IV Artesunate dose
6488.460 ng*h/mL
Interval 6488.46 to 6488.46
DHA AUC0-12 Summary Statistics for Participants With BCS of 4 in the Primary Analysis Population
Time of completion of planned IV Artesunate dosing
6488.460 ng*h/mL
Interval 6488.46 to 6488.46

PRIMARY outcome

Timeframe: Baseline, 24 hours post-first IV Artesunate dose, 48 hours post-first IV Artesunate dose, Time of completion of planned IV Artesunate dosing (72 hours post-first IV Artesunate dose), and Time of first hospital discharge (up to day 9)

Population: The PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available.

Blantyre coma scale is an ordinal scale designed to assess malarial coma in children. Eye movement, best motor response, and best verbal response were assessed and scored. The total BCS score was then calculated as the sum of the scores for these three assessments with possible values of 0, 1, 2, 3, 4, or 5. Lower BCS values were indicative of impaired consciousness. BCS was recorded daily until discharge along with scheduled follow-up visits. The number of participants in each BCS were reported at pre-defined timepoints: baseline, 24 and 48 hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time of first hospital discharge. Due to the lack of variability in BCS scores, proportional odds mixed effects models to assess the relationship between BCS scores and each PK exposure parameter were not conducted. Instead, summary statistics of DHA AUC0-12 for BCS score of 5 by timepoint are presented.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=87 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
DHA AUC0-12 Summary Statistics for Participants With BCS of 5 in the Primary Analysis Population
24 hours post-first IV Artesunate dose
4374.420 ng*h/mL
Interval 1966.87 to 9390.38
DHA AUC0-12 Summary Statistics for Participants With BCS of 5 in the Primary Analysis Population
Baseline
4377.195 ng*h/mL
Interval 1966.87 to 9390.38
DHA AUC0-12 Summary Statistics for Participants With BCS of 5 in the Primary Analysis Population
48 hours post-first IV Artesunate dose
4374.420 ng*h/mL
Interval 1966.87 to 9390.38
DHA AUC0-12 Summary Statistics for Participants With BCS of 5 in the Primary Analysis Population
Time of completion of planned IV Artesunate dosing
4377.195 ng*h/mL
Interval 1966.87 to 9390.38
DHA AUC0-12 Summary Statistics for Participants With BCS of 5 in the Primary Analysis Population
Time of first hospital discharge
4377.195 ng*h/mL
Interval 1966.87 to 9390.38

PRIMARY outcome

Timeframe: Baseline, 24 hours post-first IV Artesunate dose, 48 hours post-first IV Artesunate dose, Time of completion of planned IV Artesunate dosing (72 hours post-first IV Artesunate dose), and Time of first hospital discharge (up to day 9)

Population: Sensitivity analyses were conducted on the subset of the PD analysis population who did not receive any IV artesunate or other artemisinin-based therapy before enrollment. The PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available.

BCS is an ordinal scale designed to assess malarial coma in children. Eye movement, best motor response, and best verbal response were assessed and scored. The total BCS score was then calculated as the sum of the scores for these three assessments with possible values of 0, 1, 2, 3, 4, or 5. Lower BCS values were indicative of impaired consciousness. BCS was recorded daily until discharge along with scheduled follow-up visits. The number of participants in each BCS were reported at pre-defined timepoints: baseline, 24 and 48 hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time of first hospital discharge. Due to the lack of variability in BCS scores, proportional odds mixed effects models to assess the relationship between BCS scores and each PK exposure parameter were not conducted. Instead, summary statistics of DHA AUC0-12 for BCS score of 4 by timepoint are presented. Only participants who were assessed a BCS of 4 are shown.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=63 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
DHA AUC0-12 Summary Statistics for Participants With BCS of 4 in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Baseline
4054.710 ng*h/mL
Interval 4054.71 to 4054.71

PRIMARY outcome

Timeframe: Baseline, 24 hours post-first IV Artesunate dose, 48 hours post-first IV Artesunate dose, Time of completion of planned IV Artesunate dosing (72 hours post-first IV Artesunate dose), and Time of first hospital discharge (up to day 9)

Population: Sensitivity analyses were conducted on the subset of the PD analysis population who did not receive any IV artesunate or other artemisinin-based therapy before enrollment. The PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available.

Blantyre coma scale is an ordinal scale designed to assess malarial coma in children. Eye movement, best motor response, and best verbal response were assessed and scored. The total BCS score was then calculated as the sum of the scores for these three assessments with possible values of 0, 1, 2, 3, 4, or 5. Lower BCS values were indicative of impaired consciousness. BCS was recorded daily until discharge along with scheduled follow-up visits. The number of participants in each BCS were reported at pre-defined timepoints: baseline, 24 and 48 hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time of first hospital discharge. Due to the lack of variability in BCS scores, proportional odds mixed effects models to assess the relationship between BCS scores and each PK exposure parameter were not conducted. Instead, summary statistics of DHA AUC0-12 for BCS score of 5 by timepoint are presented.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=63 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
DHA AUC0-12 Summary Statistics for Participants With BCS of 5 in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Baseline
4417.875 ng*h/mL
Interval 1966.87 to 7070.97
DHA AUC0-12 Summary Statistics for Participants With BCS of 5 in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
24 hours post-first IV Artesunate dose
4379.970 ng*h/mL
Interval 1966.87 to 7070.97
DHA AUC0-12 Summary Statistics for Participants With BCS of 5 in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
48 hours post-first IV Artesunate dose
4379.970 ng*h/mL
Interval 1966.87 to 7070.97
DHA AUC0-12 Summary Statistics for Participants With BCS of 5 in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Time of completion of planned IV Artesunate dosing
4379.970 ng*h/mL
Interval 1966.87 to 7070.97
DHA AUC0-12 Summary Statistics for Participants With BCS of 5 in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Time of first hospital discharge
4377.195 ng*h/mL
Interval 1966.87 to 7070.97

PRIMARY outcome

Timeframe: Baseline, 24 hours post-first IV Artesunate dose, 48 hours post-first IV Artesunate dose, Time of completion of planned IV Artesunate dosing (72 hours post-first IV Artesunate dose), and Time of first hospital discharge (up to day 9)

Population: The PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available. Only participants who were assessed a BCS of 1 are shown.

Blantyre coma scale is an ordinal scale designed to assess malarial coma in children. Eye movement, best motor response, and best verbal response were assessed and scored. The total BCS score was then calculated as the sum of the scores for these three assessments with possible values of 0, 1, 2, 3, 4, or 5. Lower BCS values were indicative of impaired consciousness. BCS was recorded daily until discharge along with scheduled follow-up visits. The number of participants in each BCS were reported at pre-defined timepoints: baseline, 24 and 48 hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time of first hospital discharge. Due to the lack of variability in BCS scores, proportional odds mixed effects models to assess the relationship between BCS scores and each PK exposure parameter were not conducted. Instead, summary statistics of DHA Cmax for BCS score of 1 by timepoint are presented.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=87 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
DHA Cmax Summary Statistics for Participants With BCS of 1 in the Primary Analysis Population
Baseline
4361.170 ng/mL
Interval 4361.17 to 4361.17
DHA Cmax Summary Statistics for Participants With BCS of 1 in the Primary Analysis Population
24 hours post-first IV Artesunate dose
4361.170 ng/mL
Interval 4361.17 to 4361.17
DHA Cmax Summary Statistics for Participants With BCS of 1 in the Primary Analysis Population
48 hours post-first IV Artesunate dose
4361.170 ng/mL
Interval 4361.17 to 4361.17

PRIMARY outcome

Timeframe: Baseline, 24 hours post-first IV Artesunate dose, 48 hours post-first IV Artesunate dose, Time of completion of planned IV Artesunate dosing (72 hours post-first IV Artesunate dose), and Time of first hospital discharge (up to day 9)

Population: The PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available. Only participants who were assessed a BCS of 4 are shown.

Blantyre coma scale is an ordinal scale designed to assess malarial coma in children. Eye movement, best motor response, and best verbal response were assessed and scored. The total BCS score was then calculated as the sum of the scores for these three assessments with possible values of 0, 1, 2, 3, 4, or 5. Lower BCS values were indicative of impaired consciousness. BCS was recorded daily until discharge along with scheduled follow-up visits. The number of participants in each BCS were reported at pre-defined timepoints: baseline, 24 and 48 hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time of first hospital discharge. Due to the lack of variability in BCS scores, proportional odds mixed effects models to assess the relationship between BCS scores and each PK exposure parameter were not conducted. Instead, summary statistics of DHA Cmax for BCS score of 4 by timepoint are presented.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=87 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
DHA Cmax Summary Statistics for Participants With BCS of 4 in the Primary Analysis Population
Baseline
4361.905 ng/mL
Interval 4361.09 to 4362.72
DHA Cmax Summary Statistics for Participants With BCS of 4 in the Primary Analysis Population
24 hours post-first IV Artesunate dose
4362.720 ng/mL
Interval 4362.72 to 4362.72
DHA Cmax Summary Statistics for Participants With BCS of 4 in the Primary Analysis Population
48 hours post-first IV Artesunate dose
4362.720 ng/mL
Interval 4362.72 to 4362.72
DHA Cmax Summary Statistics for Participants With BCS of 4 in the Primary Analysis Population
Time of completion of planned IV Artesunate dosing
4362.720 ng/mL
Interval 4362.72 to 4362.72

PRIMARY outcome

Timeframe: Baseline, 24 hours post-first IV Artesunate dose, 48 hours post-first IV Artesunate dose, Time of completion of planned IV Artesunate dosing (72 hours post-first IV Artesunate dose), and Time of first hospital discharge (up to day 9)

Population: The PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available.

Blantyre coma scale is an ordinal scale designed to assess malarial coma in children. Eye movement, best motor response, and best verbal response were assessed and scored. The total BCS score was then calculated as the sum of the scores for these three assessments with possible values of 0, 1, 2, 3, 4, or 5. Lower BCS values were indicative of impaired consciousness. BCS was recorded daily until discharge along with scheduled follow-up visits. The number of participants in each BCS were reported at pre-defined timepoints: baseline, 24 and 48 hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time of first hospital discharge. Due to the lack of variability in BCS scores, proportional odds mixed effects models to assess the relationship between BCS scores and each PK exposure parameter were not conducted. Instead, summary statistics of DHA Cmax for BCS score of 5 by timepoint are presented.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=87 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
DHA Cmax Summary Statistics for Participants With BCS of 5 in the Primary Analysis Population
Baseline
4361.090 ng/mL
Interval 3488.88 to 4368.38
DHA Cmax Summary Statistics for Participants With BCS of 5 in the Primary Analysis Population
24 hours post-first IV Artesunate dose
4361.090 ng/mL
Interval 3488.88 to 4368.38
DHA Cmax Summary Statistics for Participants With BCS of 5 in the Primary Analysis Population
48 hours post-first IV Artesunate dose
4361.090 ng/mL
Interval 3488.88 to 4368.38
DHA Cmax Summary Statistics for Participants With BCS of 5 in the Primary Analysis Population
Time of completion of planned IV Artesunate dosing
4361.090 ng/mL
Interval 3488.88 to 4368.38
DHA Cmax Summary Statistics for Participants With BCS of 5 in the Primary Analysis Population
Time of first hospital discharge
4361.090 ng/mL
Interval 3488.88 to 4368.38

PRIMARY outcome

Timeframe: Baseline, 24 hours post-first IV Artesunate dose, 48 hours post-first IV Artesunate dose, Time of completion of planned IV Artesunate dosing (72 hours post-first IV Artesunate dose), and Time of first hospital discharge (up to day 9)

Population: Sensitivity analyses were conducted on the subset of the PD analysis population who did not receive any IV artesunate or other artemisinin-based therapy before enrollment. The PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available.

Blantyre coma scale is an ordinal scale designed to assess malarial coma in children. Eye movement, best motor response, and best verbal response were assessed and scored. The total BCS score was then calculated as the sum of the scores for these three assessments with possible values of 0, 1, 2, 3, 4, or 5. Lower BCS values were indicative of impaired consciousness. BCS was recorded daily until discharge along with scheduled follow-up visits. The number of participants in each BCS were reported at pre-defined timepoints: baseline, 24 and 48 hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time of first hospital discharge. Due to the lack of variability in BCS scores, proportional odds mixed effects models to assess the relationship between BCS scores and each PK exposure parameter were not conducted. Instead, summary statistics of DHA Cmax for BCS score of 4 by timepoint are presented. Only participants who were assessed a BCS of 4 are shown.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=63 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
DHA Cmax Summary Statistics for Participants With BCS of 4 in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Baseline
4361.090 ng/mL
Interval 4361.09 to 4361.09

PRIMARY outcome

Timeframe: Baseline, 24 hours post-first IV Artesunate dose, 48 hours post-first IV Artesunate dose, Time of completion of planned IV Artesunate dosing (72 hours post-first IV Artesunate dose), and Time of first hospital discharge (up to day 9)

Population: Sensitivity analyses were conducted on the subset of the PD analysis population who did not receive any IV artesunate or other artemisinin-based therapy before enrollment. The PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available.

Blantyre coma scale is an ordinal scale designed to assess malarial coma in children. Eye movement, best motor response, and best verbal response were assessed and scored. The total BCS score was then calculated as the sum of the scores for these three assessments with possible values of 0, 1, 2, 3, 4, or 5. Lower BCS values were indicative of impaired consciousness. BCS was recorded daily until discharge along with scheduled follow-up visits. The number of participants in each BCS were reported at pre-defined timepoints: baseline, 24 and 48 hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time of first hospital discharge. Due to the lack of variability in BCS scores, proportional odds mixed effects models to assess the relationship between BCS scores and each PK exposure parameter were not conducted. Instead, summary statistics of DHA Cmax for BCS score of 5 by timepoint are presented.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=63 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
DHA Cmax Summary Statistics for Participants With BCS of 5 in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Baseline
4361.090 ng/mL
Interval 3488.88 to 4361.09
DHA Cmax Summary Statistics for Participants With BCS of 5 in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
24 hours post-first IV Artesunate dose
4361.090 ng/mL
Interval 3488.88 to 4361.09
DHA Cmax Summary Statistics for Participants With BCS of 5 in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
48 hours post-first IV Artesunate dose
4361.090 ng/mL
Interval 3488.88 to 4361.09
DHA Cmax Summary Statistics for Participants With BCS of 5 in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Time of completion of planned IV Artesunate dosing
4361.090 ng/mL
Interval 3488.88 to 4361.09
DHA Cmax Summary Statistics for Participants With BCS of 5 in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Time of first hospital discharge
4361.090 ng/mL
Interval 3488.88 to 4361.09

PRIMARY outcome

Timeframe: Baseline, 24 hours post-first IV Artesunate dose, 48 hours post-first IV Artesunate dose, Time of completion of planned IV Artesunate dosing (72 hours post-first IV Artesunate dose), and Time of first hospital discharge (up to day 9)

Population: The PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available. Only participants who were assessed a BCS of 1 are shown.

Blantyre coma scale is an ordinal scale designed to assess malarial coma in children. Eye movement, best motor response, and best verbal response were assessed and scored. The total BCS score was then calculated as the sum of the scores for these three assessments with possible values of 0, 1, 2, 3, 4, or 5. Lower BCS values were indicative of impaired consciousness. BCS was recorded daily until discharge along with scheduled follow-up visits. The number of participants in each BCS were reported at pre-defined timepoints: baseline, 24 and 48 hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time of first hospital discharge. Due to the lack of variability in BCS scores, proportional odds mixed effects models to assess the relationship between BCS scores and each PK exposure parameter were not conducted. Instead, summary statistics of DHA t1/2 for BCS score of 1 by timepoint are presented.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=87 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
DHA t1/2 Summary Statistics for Participants With BCS of 1 in the Primary Analysis Population
Baseline
0.850 h
Interval 0.85 to 0.85
DHA t1/2 Summary Statistics for Participants With BCS of 1 in the Primary Analysis Population
24 hours post-first IV Artesunate dose
0.850 h
Interval 0.85 to 0.85
DHA t1/2 Summary Statistics for Participants With BCS of 1 in the Primary Analysis Population
48 hours post-first IV Artesunate dose
0.850 h
Interval 0.85 to 0.85

PRIMARY outcome

Timeframe: Baseline, 24 hours post-first IV Artesunate dose, 48 hours post-first IV Artesunate dose, Time of completion of planned IV Artesunate dosing (72 hours post-first IV Artesunate dose), and Time of first hospital discharge (up to day 9)

Population: The PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available. Only participants who were assessed a BCS of 4 are shown.

Blantyre coma scale is an ordinal scale designed to assess malarial coma in children. Eye movement, best motor response, and best verbal response were assessed and scored. The total BCS score was then calculated as the sum of the scores for these three assessments with possible values of 0, 1, 2, 3, 4, or 5. Lower BCS values were indicative of impaired consciousness. BCS was recorded daily until discharge along with scheduled follow-up visits. The number of participants in each BCS were reported at pre-defined timepoints: baseline, 24 and 48 hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time of first hospital discharge. Due to the lack of variability in BCS scores, proportional odds mixed effects models to assess the relationship between BCS scores and each PK exposure parameter were not conducted. Instead, summary statistics of DHA t1/2 for BCS score of 4 by timepoint are presented.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=87 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
DHA t1/2 Summary Statistics for Participants With BCS of 4 in the Primary Analysis Population
Baseline
0.835 h
Interval 0.64 to 1.03
DHA t1/2 Summary Statistics for Participants With BCS of 4 in the Primary Analysis Population
24 hours post-first IV Artesunate dose
1.030 h
Interval 1.03 to 1.03
DHA t1/2 Summary Statistics for Participants With BCS of 4 in the Primary Analysis Population
48 hours post-first IV Artesunate dose
1.030 h
Interval 1.03 to 1.03
DHA t1/2 Summary Statistics for Participants With BCS of 4 in the Primary Analysis Population
Time of completion of planned IV Artesunate dosing
1.030 h
Interval 1.03 to 1.03

PRIMARY outcome

Timeframe: Baseline, 24 hours post-first IV Artesunate dose, 48 hours post-first IV Artesunate dose, Time of completion of planned IV Artesunate dosing (72 hours post-first IV Artesunate dose), and Time of first hospital discharge (up to day 9)

Population: The PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available.

Blantyre coma scale is an ordinal scale designed to assess malarial coma in children. Eye movement, best motor response, and best verbal response were assessed and scored. The total BCS score was then calculated as the sum of the scores for these three assessments with possible values of 0, 1, 2, 3, 4, or 5. Lower BCS values were indicative of impaired consciousness. BCS was recorded daily until discharge along with scheduled follow-up visits. The number of participants in each BCS were reported at pre-defined timepoints: baseline, 24 and 48 hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time of first hospital discharge. Due to the lack of variability in BCS scores, proportional odds mixed effects models to assess the relationship between BCS scores and each PK exposure parameter were not conducted. Instead, summary statistics of DHA t1/2 for BCS score of 5 by timepoint are presented.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=87 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
DHA t1/2 Summary Statistics for Participants With BCS of 5 in the Primary Analysis Population
Baseline
0.740 h
Interval 0.39 to 1.5
DHA t1/2 Summary Statistics for Participants With BCS of 5 in the Primary Analysis Population
24 hours post-first IV Artesunate dose
0.740 h
Interval 0.39 to 1.5
DHA t1/2 Summary Statistics for Participants With BCS of 5 in the Primary Analysis Population
48 hours post-first IV Artesunate dose
0.740 h
Interval 0.39 to 1.5
DHA t1/2 Summary Statistics for Participants With BCS of 5 in the Primary Analysis Population
Time of completion of planned IV Artesunate dosing
0.740 h
Interval 0.39 to 1.5
DHA t1/2 Summary Statistics for Participants With BCS of 5 in the Primary Analysis Population
Time of first hospital discharge
0.740 h
Interval 0.39 to 1.5

PRIMARY outcome

Timeframe: Baseline, 24 hours post-first IV Artesunate dose, 48 hours post-first IV Artesunate dose, Time of completion of planned IV Artesunate dosing (72 hours post-first IV Artesunate dose), and Time of first hospital discharge (up to day 9)

Population: Sensitivity analyses were conducted on the subset of the PD analysis population who did not receive any IV artesunate or other artemisinin-based therapy before enrollment. The PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available.

Blantyre coma scale is an ordinal scale designed to assess malarial coma in children. Eye movement, best motor response, and best verbal response were assessed and scored. The total BCS score was then calculated as the sum of the scores for these three assessments with possible values of 0, 1, 2, 3, 4, or 5. Lower BCS values were indicative of impaired consciousness. BCS was recorded daily until discharge along with scheduled follow-up visits. The number of participants in each BCS were reported at pre-defined timepoints: baseline, 24 and 48 hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time of first hospital discharge. Due to the lack of variability in BCS scores, proportional odds mixed effects models to assess the relationship between BCS scores and each PK exposure parameter were not conducted. Instead, summary statistics of DHA t1/2 for BCS score of 4 by timepoint are presented. Only participants who were assessed a BCS of 4 are shown.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=63 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
DHA t1/2 Summary Statistics for Participants With BCS of 4 in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Baseline
0.640 h
Interval 0.64 to 0.64

PRIMARY outcome

Timeframe: Baseline, 24 hours post-first IV Artesunate dose, 48 hours post-first IV Artesunate dose, Time of completion of planned IV Artesunate dosing (72 hours post-first IV Artesunate dose), and Time of first hospital discharge (up to day 9)

Population: Sensitivity analyses were conducted on the subset of the PD analysis population who did not receive any IV artesunate or other artemisinin-based therapy before enrollment. The PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available.

Blantyre coma scale is an ordinal scale designed to assess malarial coma in children. Eye movement, best motor response, and best verbal response were assessed and scored. The total BCS score was then calculated as the sum of the scores for these three assessments with possible values of 0, 1, 2, 3, 4, or 5. Lower BCS values were indicative of impaired consciousness. BCS was recorded daily until discharge along with scheduled follow-up visits. The number of participants in each BCS were reported at pre-defined timepoints: baseline, 24 and 48 hours post-first IV artesunate, time of completion of planned IV artesunate dosing, and time of first hospital discharge. Due to the lack of variability in BCS scores, proportional odds mixed effects models to assess the relationship between BCS scores and each PK exposure parameter were not conducted. Instead, summary statistics of DHA t1/2 for BCS score of 5 by timepoint are presented.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=63 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
DHA t1/2 Summary Statistics for Participants With BCS of 5 in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Baseline
0.740 h
Interval 0.39 to 1.12
DHA t1/2 Summary Statistics for Participants With BCS of 5 in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
24 hours post-first IV Artesunate dose
0.740 h
Interval 0.39 to 1.12
DHA t1/2 Summary Statistics for Participants With BCS of 5 in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
48 hours post-first IV Artesunate dose
0.740 h
Interval 0.39 to 1.12
DHA t1/2 Summary Statistics for Participants With BCS of 5 in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Time of completion of planned IV Artesunate dosing
0.740 h
Interval 0.39 to 1.12
DHA t1/2 Summary Statistics for Participants With BCS of 5 in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Time of first hospital discharge
0.740 h
Interval 0.39 to 1.12

SECONDARY outcome

Timeframe: Day 1 through Day 9

Population: The PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available.

Dates and times of hospital admittance and discharge for each participant were collected for calculation of time to hospital discharge. Time to hospital discharge was defined as the time in days from initial participant admission to the time of first discharge. Time to hospital discharge was calculated using the actual dates and times of initial participant admission and first discharge and was rounded to the nearest tenths place.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=84 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
Time to Hospital Discharge in the Primary Analysis Population
2.65 days
Interval 1.9 to 8.3

SECONDARY outcome

Timeframe: Day 1 through Day 9

Population: Sensitivity analyses were conducted on the subset of the PD analysis population who did not receive any IV artesunate or other artemisinin-based therapy before enrollment. The PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available.

Dates and times of hospital admittance and discharge for each participant were collected for calculation of time to hospital discharge. Time to hospital discharge was defined as the time in days from initial participant admission to the time of first discharge. Time to hospital discharge was calculated using the actual dates and times of initial participant admission and first discharge and was rounded to the nearest tenths place.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=62 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
Time to Hospital Discharge in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
2.20 days
Interval 1.9 to 8.3

SECONDARY outcome

Timeframe: Day 1 through Day 7 (Samples were collected according to the following schedule post-first on-study dose of IV artesunate in hours: 0, 6, 12, 24, 36, and 48 hours, and at least every 24 hours until clearance.)

Population: The PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available.

Parasite clearance as calculated from parasite density over time, as measured by thick blood smear. Parasite density is defined as the number of parasites per 200 white blood cells (WBCs). Parasite clearance half-life (PCT50) and parasite clearance time to 90% reduction (PCT90) were estimated using the WorldWide Antimalarial Resistance Network (WWARN) parasite clearance estimator (PCE) algorithm.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=87 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
Parasite (Plasmodium Falciparum) Density in Thick Blood Smear in the Primary Analysis Population
0 (0-2)h
620.5 parasites/200 WBCs
Interval 1.0 to 10800.0
Parasite (Plasmodium Falciparum) Density in Thick Blood Smear in the Primary Analysis Population
6 (4-8) h
352.0 parasites/200 WBCs
Interval 0.0 to 8080.0
Parasite (Plasmodium Falciparum) Density in Thick Blood Smear in the Primary Analysis Population
12 (10-14) h
168.0 parasites/200 WBCs
Interval 0.0 to 1844.0
Parasite (Plasmodium Falciparum) Density in Thick Blood Smear in the Primary Analysis Population
24 (22-26) h
6.0 parasites/200 WBCs
Interval 0.0 to 964.0
Parasite (Plasmodium Falciparum) Density in Thick Blood Smear in the Primary Analysis Population
36 (34-38) h
1.0 parasites/200 WBCs
Interval 0.0 to 460.0
Parasite (Plasmodium Falciparum) Density in Thick Blood Smear in the Primary Analysis Population
48 (46-50) h
1.0 parasites/200 WBCs
Interval 0.0 to 464.0
Parasite (Plasmodium Falciparum) Density in Thick Blood Smear in the Primary Analysis Population
Day 3
0.0 parasites/200 WBCs
Interval 0.0 to 28.0
Parasite (Plasmodium Falciparum) Density in Thick Blood Smear in the Primary Analysis Population
Day 4
0.5 parasites/200 WBCs
Interval 0.0 to 90.0
Parasite (Plasmodium Falciparum) Density in Thick Blood Smear in the Primary Analysis Population
Day 5
0.0 parasites/200 WBCs
Interval 0.0 to 5.0
Parasite (Plasmodium Falciparum) Density in Thick Blood Smear in the Primary Analysis Population
Day 6
0.0 parasites/200 WBCs
Interval 0.0 to 2.0
Parasite (Plasmodium Falciparum) Density in Thick Blood Smear in the Primary Analysis Population
Day 7
0.0 parasites/200 WBCs
Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: Day 1 through Day 7 (Samples were collected according to the following schedule post-first on-study dose of IV artesunate in hours: 0, 6, 12, 24, 36, and 48 hours, and at least every 24 hours until clearance.)

Population: Sensitivity analyses were conducted on the subset of the PD analysis population who did not receive any IV artesunate or other artemisinin-based therapy before enrollment. The PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available.

Parasite clearance as calculated from parasite density over time, as measured by thick blood smear. Parasite density is defined as the number of parasites per 200 white blood cells (WBCs). Parasite clearance half-life (PCT50) and parasite clearance time to 90% reduction (PCT90) were estimated using the WorldWide Antimalarial Resistance Network (WWARN) parasite clearance estimator (PCE) algorithm.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=63 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
Parasite (P. Falciparum) Density in Thick Blood Smear in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
0 (0-2)h
694.0 parasites/200 WBCs
Interval 1.0 to 10800.0
Parasite (P. Falciparum) Density in Thick Blood Smear in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
6 (4-8) h
876.0 parasites/200 WBCs
Interval 0.0 to 8080.0
Parasite (P. Falciparum) Density in Thick Blood Smear in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
12 (10-14) h
358.0 parasites/200 WBCs
Interval 0.0 to 1844.0
Parasite (P. Falciparum) Density in Thick Blood Smear in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
24 (22-26) h
20.0 parasites/200 WBCs
Interval 0.0 to 964.0
Parasite (P. Falciparum) Density in Thick Blood Smear in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
36 (34-38) h
2.0 parasites/200 WBCs
Interval 0.0 to 460.0
Parasite (P. Falciparum) Density in Thick Blood Smear in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
48 (46-50) h
1.0 parasites/200 WBCs
Interval 0.0 to 464.0
Parasite (P. Falciparum) Density in Thick Blood Smear in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Day 3
0.0 parasites/200 WBCs
Interval 0.0 to 28.0
Parasite (P. Falciparum) Density in Thick Blood Smear in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Day 4
1.0 parasites/200 WBCs
Interval 0.0 to 90.0
Parasite (P. Falciparum) Density in Thick Blood Smear in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Day 5
0.0 parasites/200 WBCs
Interval 0.0 to 5.0
Parasite (P. Falciparum) Density in Thick Blood Smear in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Day 6
0.0 parasites/200 WBCs
Interval 0.0 to 2.0
Parasite (P. Falciparum) Density in Thick Blood Smear in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Day 7
0.0 parasites/200 WBCs
Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: Day 1 through Day 7 (Samples were collected according to the following schedule post-first on-study dose of IV artesunate in hours: 0, 6, 12, 24, 36, and 48 hours, and at least every 24 hours until clearance.)

Population: The PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available.

Total parasite clearance was defined as the first negative thick blood smear (i.e., a thick blood smear for which there were no detectable P. falciparum parasites per 200 WBC) after a participant's last positive blood smear for P. falciparum. The date and time of total parasite clearance was defined as the collection date and time of the first thick blood smear to meet the definition of parasite clearance. Total parasite clearance by Day 2 was defined as a binary variable indicating whether total parasite clearance occurred within the first 50 hours post-first on-study dose of IV artesunate.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=87 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
Number of Participants With Parasite (P. Falciparum) Clearance in the Primary Analysis Population
0 (0-2)h
0 Participants
Number of Participants With Parasite (P. Falciparum) Clearance in the Primary Analysis Population
6 (4-8) h
1 Participants
Number of Participants With Parasite (P. Falciparum) Clearance in the Primary Analysis Population
12 (10-14) h
3 Participants
Number of Participants With Parasite (P. Falciparum) Clearance in the Primary Analysis Population
24 (22-26) h
12 Participants
Number of Participants With Parasite (P. Falciparum) Clearance in the Primary Analysis Population
36 (34-38) h
32 Participants
Number of Participants With Parasite (P. Falciparum) Clearance in the Primary Analysis Population
48 (46-50) h
48 Participants
Number of Participants With Parasite (P. Falciparum) Clearance in the Primary Analysis Population
Day 3
48 Participants
Number of Participants With Parasite (P. Falciparum) Clearance in the Primary Analysis Population
Day 4
59 Participants
Number of Participants With Parasite (P. Falciparum) Clearance in the Primary Analysis Population
Day 5
76 Participants
Number of Participants With Parasite (P. Falciparum) Clearance in the Primary Analysis Population
Day 6
81 Participants
Number of Participants With Parasite (P. Falciparum) Clearance in the Primary Analysis Population
Day 7
83 Participants

SECONDARY outcome

Timeframe: Day 1 through Day 7 (Samples were collected according to the following schedule post-first on-study dose of IV artesunate in hours: 0, 6, 12, 24, 36, and 48 hours, and at least every 24 hours until clearance.)

Population: Sensitivity analyses were conducted on the subset of the PD analysis population who did not receive any IV artesunate or other artemisinin-based therapy before enrollment. The PD analysis population included all participants meeting the definition of severe malaria at enrollment that received \< 24 hours of artemisinin therapy prior to enrollment for which exposure parameters were estimated from the final population PK model and for which post-baseline response data were available.

Total parasite clearance was defined as the first negative thick blood smear (i.e., a thick blood smear for which there were no detectable P. falciparum parasites per 200 WBC) after a participant's last positive blood smear for P. falciparum. The date and time of total parasite clearance was defined as the collection date and time of the first thick blood smear to meet the definition of parasite clearance. Total parasite clearance by Day 2 was defined as a binary variable indicating whether total parasite clearance occurred within the first 50 hours post-first on-study dose of IV artesunate.

Outcome measures

Outcome measures
Measure
Standard of Care IV Artesunate
n=63 Participants
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
Number of Participants With Parasite (P. Falciparum) Clearance in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
0 (0-2)h
0 Participants
Number of Participants With Parasite (P. Falciparum) Clearance in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
6 (4-8) h
1 Participants
Number of Participants With Parasite (P. Falciparum) Clearance in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
12 (10-14) h
1 Participants
Number of Participants With Parasite (P. Falciparum) Clearance in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
24 (22-26) h
6 Participants
Number of Participants With Parasite (P. Falciparum) Clearance in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
36 (34-38) h
22 Participants
Number of Participants With Parasite (P. Falciparum) Clearance in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
48 (46-50) h
33 Participants
Number of Participants With Parasite (P. Falciparum) Clearance in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Day 3
33 Participants
Number of Participants With Parasite (P. Falciparum) Clearance in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Day 4
42 Participants
Number of Participants With Parasite (P. Falciparum) Clearance in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Day 5
55 Participants
Number of Participants With Parasite (P. Falciparum) Clearance in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Day 6
59 Participants
Number of Participants With Parasite (P. Falciparum) Clearance in the Subset Who Did Not Receive Any IV Artesunate or Other Artemisinin-based Therapy Before Enrollment
Day 7
61 Participants

Adverse Events

Standard of Care IV Artesunate

Serious events: 4 serious events
Other events: 35 other events
Deaths: 2 deaths

Serious adverse events

Serious adverse events
Measure
Standard of Care IV Artesunate
n=90 participants at risk
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
Metabolism and nutrition disorders
Acidosis
1.1%
1/90 • Number of events 1 • All AEs and SAEs were documented from time of study product administration (Day 1) through the time of the last assessment (Day 183).
Infections and infestations
Complicated Malaria
1.1%
1/90 • Number of events 1 • All AEs and SAEs were documented from time of study product administration (Day 1) through the time of the last assessment (Day 183).
Nervous system disorders
Seizure
1.1%
1/90 • Number of events 1 • All AEs and SAEs were documented from time of study product administration (Day 1) through the time of the last assessment (Day 183).
Infections and infestations
Cerebral malaria
1.1%
1/90 • Number of events 1 • All AEs and SAEs were documented from time of study product administration (Day 1) through the time of the last assessment (Day 183).

Other adverse events

Other adverse events
Measure
Standard of Care IV Artesunate
n=90 participants at risk
Participants received IV Artesunate at times 0, 12, and 24, 48, and 72 hours relative to time of first dose. Participants who recovered after at least 24 hours of IV artesunate administration and were able to transition to oral antimalarial therapy initiated a three-day course of oral artemether-lumefantrine, an ACT, per national guidelines. If the participant was discharged from the hospital prior to completion of an oral ACT regimen, treatment was continued on an outpatient basis.
Infections and infestations
Upper respiratory tract infection
26.7%
24/90 • Number of events 26 • All AEs and SAEs were documented from time of study product administration (Day 1) through the time of the last assessment (Day 183).
Infections and infestations
Malaria
11.1%
10/90 • Number of events 11 • All AEs and SAEs were documented from time of study product administration (Day 1) through the time of the last assessment (Day 183).
Infections and infestations
Bacteraemia
5.6%
5/90 • Number of events 5 • All AEs and SAEs were documented from time of study product administration (Day 1) through the time of the last assessment (Day 183).
Infections and infestations
Gastroenteritis
5.6%
5/90 • Number of events 5 • All AEs and SAEs were documented from time of study product administration (Day 1) through the time of the last assessment (Day 183).

Additional Information

Matthew B. Laurens, MD, MPH

University of Maryland

Phone: 410-706-5462

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place